Dermira (NASDAQ:DERM)‘s stock had its “buy” rating restated by stock analysts at Cantor Fitzgerald in a note issued to investors on Wednesday. They currently have a $20.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price indicates a potential upside of 60.00% from the stock’s previous close.
The analysts wrote, “. Post DERM’s solid quarter of execution, we reiterate our OW rating and 12-month price target of $20 for DERM shares. We think there is not enough value being attributed to DERM’s two key assets: 1) Qbrexza (glycopyrronium) for hyperhidrosis (excessive sweating) and 2) lebrikizumab for atopic dermatitis. The launch of Qbrexza and pipeline advancements for lebrikizumab should drive upward earnings revisions to levels not yet reflected in sell-side consensus expectations and DERM’s stock higher.””
A number of other research firms have also recently commented on DERM. BidaskClub cut Dermira from a “buy” rating to a “hold” rating in a research note on Friday, August 17th. Zacks Investment Research cut Dermira from a “hold” rating to a “sell” rating in a research note on Monday, August 13th. ValuEngine upgraded Dermira from a “strong sell” rating to a “sell” rating in a research note on Tuesday, October 2nd. Finally, Mizuho restated a “hold” rating and set a $10.00 price target on shares of Dermira in a research note on Tuesday, October 2nd. Four analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. Dermira currently has a consensus rating of “Buy” and a consensus price target of $22.86.
NASDAQ:DERM traded up $0.29 during trading hours on Wednesday, reaching $12.50. 713,500 shares of the stock were exchanged, compared to its average volume of 1,003,096. The company has a quick ratio of 4.78, a current ratio of 4.78 and a debt-to-equity ratio of 2.49. Dermira has a twelve month low of $6.98 and a twelve month high of $31.42. The stock has a market capitalization of $536.26 million, a price-to-earnings ratio of -2.85 and a beta of 0.96.
Dermira (NASDAQ:DERM) last released its quarterly earnings results on Monday, August 6th. The biopharmaceutical company reported ($0.57) EPS for the quarter, hitting analysts’ consensus estimates of ($0.57). Dermira had a negative return on equity of 128.21% and a negative net margin of 761.87%. The company had revenue of $39.08 million for the quarter, compared to analysts’ expectations of $39.00 million. On average, sell-side analysts expect that Dermira will post -5.46 EPS for the current fiscal year.
In other news, Director Matthew K. Fust sold 4,000 shares of the company’s stock in a transaction on Friday, October 19th. The stock was sold at an average price of $13.75, for a total transaction of $55,000.00. Following the sale, the director now owns 14,051 shares of the company’s stock, valued at $193,201.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 14.80% of the stock is currently owned by corporate insiders.
Several institutional investors have recently bought and sold shares of DERM. Wells Fargo & Company MN increased its position in shares of Dermira by 31.9% during the first quarter. Wells Fargo & Company MN now owns 32,772 shares of the biopharmaceutical company’s stock worth $262,000 after acquiring an additional 7,924 shares during the period. Dimensional Fund Advisors LP increased its position in shares of Dermira by 129.9% during the first quarter. Dimensional Fund Advisors LP now owns 320,238 shares of the biopharmaceutical company’s stock worth $2,559,000 after acquiring an additional 180,947 shares during the period. Barclays PLC increased its position in shares of Dermira by 276.7% during the first quarter. Barclays PLC now owns 17,499 shares of the biopharmaceutical company’s stock worth $140,000 after acquiring an additional 12,854 shares during the period. Guggenheim Capital LLC increased its position in shares of Dermira by 26.9% during the first quarter. Guggenheim Capital LLC now owns 287,779 shares of the biopharmaceutical company’s stock worth $2,298,000 after acquiring an additional 60,929 shares during the period. Finally, Cubist Systematic Strategies LLC increased its position in shares of Dermira by 110.3% during the first quarter. Cubist Systematic Strategies LLC now owns 30,100 shares of the biopharmaceutical company’s stock worth $240,000 after acquiring an additional 15,786 shares during the period. 80.97% of the stock is currently owned by institutional investors and hedge funds.
Dermira, Inc, a biopharmaceutical company, identifies, develops, and commercializes therapies to treat dermatologic diseases. The company's product candidates include Glycopyrronium tosylate, a novel form of an anticholinergic agent that has completed Phase III clinical trial for the treatment of primary axillary hyperhidrosis; Olumacostat glasaretil, a novel small molecule designed to target sebum production, which is in Phase III clinical trial for the treatment of acne vulgaris; and lebrikizumab, a novel humanized monoclonal antibody targeting interleukin 13 that is in Phase 2b development for the treatment of moderate-to-severe atopic dermatitis.
Featured Story: Risk Tolerance
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.